Peloton Therapeutics Appoints Mohammad Hirmand, M.D., as Chief Medical Officer
April 3, 2017, 8:00 AM Eastern Daylight Time
DALLAS, TX – (BUSINESS WIRE) – Peloton Therapeutics, Inc., a drug discovery and development company focused on advancing novel small molecule cancer therapies, announced today the appointment of Mohammad Hirmand, M.D., as Chief Medical Officer. Dr. Hirmand will assume his new role on the executive management team on May 1, 2017 and will lead the Company’s clinical drug development forward.
“Dr. Hirmand is a solid leader and clinician with an impressive track record of successfully developing novel medicines in oncology,” said John A. Josey, Ph.D., Peloton’s Chief Executive Officer. “He brings to Peloton a keen ability to focus and drive an asset to a successful outcome, from discovery to regulatory review, and he is well-versed in pharmaceutical partnering. We are delighted to welcome Mohammad to our team at this critical time.”
Dr. Hirmand most recently served as Chief Medical Officer at Medivation (recently acquired by Pfizer), where he played a vital role in advancing XTANDI® (enzalutamide) through clinical trials that led to its approval by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer. His responsibilities also included the in-licensing and global clinical development of the poly ADP ribose polymerase (PARP) inhibitor, talazoparib. Before Medivation, he was Senior Director of Clinical Development at Nuvelo, Inc. (now ARCA Biopharma), where he led the Clinical Operations, Clinical Data Management and Clinical Sciences/Medical Monitor staff. Prior to that, he served as Director of Oncology Development at SuperGen, Inc. (now Astex Pharmaceuticals, Inc.) and as Associate Director of Clinical Research at Amgen, Inc. (formerly Tularik, Inc.), where he led clinical development efforts for Tularik’s oncology trials. Early in his career, he was a Clinical Scientist and Manager of Market Development and Product Evaluation at Theravance Biopharma, Inc. Dr. Hirmand received his M.D. from Harvard Medical School and his B.A. in Biological Sciences and Economics from Cornell University.
“Peloton is working in an exciting and largely untapped area in the fight against cancer. The opportunity to advance medicines with unique and highly targeted mechanism of action, such as Peloton’s HIF-2α inhibitors, is particularly appealing,” said Dr. Hirmand. “I welcome the opportunity to join their effort to quickly and efficiently bring their novel medicines to underserved patients and the marketplace.”
About Peloton Therapeutics
Peloton Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops first-in-class, small molecule cancer therapies targeting unexploited molecular vulnerabilities. Peloton Therapeutics’ lead candidate, PT2385, is a first-in-class small molecule targeting hypoxia-inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of kidney and other cancers. To learn more about Peloton Therapeutics, visit www.pelotontherapeutics.com.
Michael F. Haller, Ph.D.
Chief Business Officer
Phone: +1 (972) 629-4100
Sam Brown Inc.
Phone: +1 (312) 961-2502